The Series A funding will support the commercial expansion of a hydrogel template used in wound management and reconstructive surgery.
FesariusTherapeutics has closed an oversubscribed $20 million Series A financing round to accelerate the commercialization of its dermal repair technology. The funding round was led by Jefferson Life Sciences and included participation from Johnson & Johnson Innovation, Empire State Development New York Ventures, and the American Society of Plastic Surgeons.
The capital will be used to expand the company’s commercial infrastructure for DermiSphere, a hydrogel dermal regeneration template. The product received clearance from the Food and Drug Administration in 2025 for the management of various wound types. FesariusTherapeutics plans to hire additional direct field representatives to increase US market coverage and pursue Breakthrough Device Designation for expanded reimbursement pathways.
Additionally, the company will advance clinical trials for its OneStep procedure. This approach involves placing the dermal regeneration template and a skin graft during a single surgery, which could eliminate the second procedure required by the current standard of care. According to the company, this has the potential to reduce patient recovery time, pain, and total cost of care.
“We are excited to support Fesarius’ vision to revolutionize deep wound care and help improve outcomes for millions of patients that require skin grafts,” says Laura Lande-Diner, managing partner, Jefferson Life Sciences, in a release. “DermiSphere is already making a difference for patients. We believe Fesarius is positioned to redefine the category.”
The DermiSphere technology uses a dual-density collagen microarchitecture designed to support the body’s natural wound-healing process through faster cellular infiltration and vascularization.
“New York is building one of the nation’s most dynamic life sciences ecosystems, and companies like Fesarius are exactly why,” says Jennifer Tegan, managing director, New York Ventures, Empire State Development, in a release. “DermiSphere is the kind of innovation we want developed and scaled here, with the potential to dramatically improve outcomes for patients while creating high-quality jobs and economic opportunity across the state.”
The investment from the American Society of Plastic Surgeons marks the organization’s first institutional investment through its venture arm.
“This inaugural investment in Fesarius marks a new chapter for ASPS Ventures, one where we move from advocates to active partners in advancing technologies developed by our members,” says Michael Costelloe, executive vice president of the American Society of Plastic Surgeons and CEO of ASPS Ventures, LLC, in a release.
FesariusTherapeutics currently maintains a commercial presence across multiple US hospital systems. The company intends to use the new capital to broaden its national market coverage and advance future applications for label expansion.
“DermiSphere is creating a new frontier in dermal repair by fundamentally changing how surgeons treat seriously destructive skin loss,” says Tom Roueche, president and CEO, FesariusTherapeutics, in a release. “Patients are experiencing promising outcomes already, and this financing accelerates our clinical programs, expands our commercial reach, and ensures that every patient can access the truly remarkable outcomes we are seeing with DermiSphere hydrogel dermal regeneration template.”
ID 459977697 © Prazis | Dreamstime.com
